Gait speed in Parkinson disease correlates with cholinergic degeneration

Neurology

Volumn 81, Issue 18, 2013, Pages 1611-1616

  Bohnen, Nicolaas I ^a,b,c   Frey, Kirk A ^a,b   Studenski, Stephanie ^d   Kotagal, Vikas ^b   Koeppe, Robert A ^a   Scott, Peter J H ^a   Albin, Roger L ^b,c   Müller, Martijn L T M ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c VAAAHS   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROTETRABENAZINE C 11; METHYL 4 PIPERIDINYLPROPIONATE ACETYLCHOLINESTERASE C 11; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; TRACER; UNCLASSIFIED DRUG; 1,3 DIOXOLANE DERIVATIVE; ACETYLCHOLINESTERASE; CARBON; DIHYDROTETRABENAZINE; METHYL PIPERONYLATE; SLC18A2 PROTEIN, HUMAN; TETRABENAZINE; VESICULAR MONOAMINE TRANSPORTER;

ADULT; AGE; AGED; ARTICLE; CASE CONTROL STUDY; CHOLINERGIC ACTIVITY; COGNITION; COMORBIDITY; COMPUTED TOMOGRAPHY SCANNER; CONTROLLED STUDY; CORTICOBASAL DEGENERATION; CROSS-SECTIONAL STUDY; DEPENDENT VARIABLE; DOPAMINERGIC ACTIVITY; FEMALE; GAIT; GENDER; HUMAN; IMAGING SYSTEM; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC GAIT DISORDER; NUCLEAR MAGNETIC RESONANCE IMAGING; PARASYMPATHETIC INNERVATION; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; STRIATONIGRAL DEGENERATION; WALKING SPEED; ANALOGS AND DERIVATIVES; ANALYSIS OF VARIANCE; BRAIN CORTEX; COGNITION DISORDERS; COMPLICATION; DIAGNOSTIC USE; ENZYMOLOGY; GAIT DISORDERS, NEUROLOGIC; METABOLISM; MIDDLE AGED; NERVE DEGENERATION; NEUROPSYCHOLOGICAL TEST; PATHOLOGY; SCINTISCANNING; VERY ELDERLY;

ACETYLCHOLINESTERASE; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; CARBON ISOTOPES; CEREBRAL CORTEX; COGNITION DISORDERS; CROSS-SECTIONAL STUDIES; DIOXOLANES; FEMALE; GAIT DISORDERS, NEUROLOGIC; HUMANS; MALE; MIDDLE AGED; NERVE DEGENERATION; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY; TETRABENAZINE; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 84888263955     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3182a9f558     Document Type: Article

References (36)

1. Giladi N, McDermott MP, Fahn S, et al. Freezing of gait in PD: prospective assessment in the DATATOP cohort. Neurology 2001;56:1712-1721.
2. Postuma RB, Lang AE, Gagnon JF, Pelletier A, Montplaisir JY. How does parkinsonism start? Prodromal parkinsonism motor changes in idiopathic REM sleep behaviour disorder. Brain 2012;135:1860-1870.
3. Guttman M, Burkholder J, Kish SJ, et al. [11C]RTI-32 PET studies of the dopamine transporter in early dopanaive Parkinson's disease: implications for the symptomatic threshold. Neurology 1997;48:1578-1583.
4. Ouchi Y, Kanno T, Okada H, et al. Changes in dopamine availability in the nigrostriatal and mesocortical dopaminergic systems by gait in Parkinson's disease. Brain 2001; 124:784-792.
5. Wu T, Hallett M. A functional MRI study of automatic movements in patients with Parkinson's disease. Brain 2005;128:2250-2259.
6. Rochester L, Yarnall AJ, Baker MR, et al. Cholinergic dysfunction contributes to gait disturbance in early Parkinson's disease. Brain 2012;135:2779-2788.
7. Bohnen NI, Muller MLTM, Kotagal V, et al. Heterogeneity of cholinergic denervation in Parkinson disease. J Cereb Blood Flow Metab 2012;32:1609-1617.
8. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinicopathologic study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
9. Goetz CG, Poewe W, Rascol O, et al. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord 2004;19: 1020-1028.
10. Thompson CJ, Kecani S, Boelen S. Evaluation of a neckshield for use during neurological studies with a whole-body PET scanner. IEEE Trans Nucl Sci 2001;48:1512-1517.
11. Shao X, Hoareau R, Hockley BG, et al. Highlighting the versatility of the Tracerlab Synthesis Modules: part 1: fully automated production of [F]labelled radiopharmaceuticals using a Tracerlab FX (FN). J Labelled Comp Radiopharm 2011;54:292-307.
12. Bohnen NI, Muller MLTM, Kotagal V, et al. Olfactory dysfunction, central cholinergic integrity and cognitive impairment in Parkinson disease. Brain 2010;133:1747-1754.
13. Bohnen NI, Albin RL, Koeppe RA, et al. Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson disease. J Cereb Blood Flow Metab 2006;26:1198-1212.
14. Minoshima S, Koeppe RA, Fessler JA, et al. Integrated and automated data analysis method for neuronal activation studies using O15 water PET. In: Uemura K, Lassen NA, Jones T, Kanno I, editors. Quantification of Brain Function to Tracer Kinetics and Image Analysis in Brain PET. Tokyo: Excerpta Medica; 1993:409-418.
15. Nagatsuka S, Fukushi K, Shinotoh H, et al. Kinetic analysis of [(11)C]MP4A using a high-radioactivity brain region that represents an integrated input function for measurement of cerebral acetylcholinesterase activity without arterial blood sampling. J Cereb Blood Flow Metab 2001;21:1354-1366.
16. Heckers S, Geula C, Mesulam M. Cholinergic innervation of the human thalamus: dual origin and differential nuclear distribution. J Comp Neurol 1992;325:68-82.
17. Koeppe RA, Frey KA, Kuhl DE, Kilbourn MR. Assessment of extrastriatal vesicular monoamine transporter binding site density using stereoisomers of [11C]dihydrotetrabenazine. J Cereb Blood Flow Metab 1999;19:1376-1384.
18. Bohnen NI, Albin RL. Cholinergic denervation occurs early in Parkinson disease. Neurology 2009;73:256-257.
19. Karachi C, Grabli D, Bernard FA, et al. Cholinergic mesencephalic neurons are involved in gait and postural disorders in Parkinson disease. J Clin Invest 2010;120:2745-2754.
20. Bohnen NI, Kaufer DI, Hendrickson R, et al. Cognitive correlates of cortical cholinergic denervation in Parkinson's disease and parkinsonian dementia. J Neurol 2006;253: 242-247.
21. Woollacott M, Shumway-Cook A. Attention and the control of posture and gait: a review of an emerging area of research. Gait Posture 2002;16:1-14.
22. Verghese J, Wang C, Lipton RB, Holtzer R, Xue X. Quantitative gait dysfunction and risk of cognitive decline and dementia. J Neurol Neurosurg Psychiatry 2007;78: 929-935.
23. Mielke MM, Roberts RO, Savica R, et al. Assessing the temporal relationship between cognition and gait: slow gait predicts cognitive decline in the mayo clinic study of aging. J Gerontol A Biol Sci Med Sci 2013;68:929- 937.
24. Lord S, Rochester L, Hetherington V, Allcock LM, Burn D. Executive dysfunction and attention contribute to gait interference in 'off' state Parkinson's disease. Gait Posture 2010;31:169-174.
25. Fried LP, Xue QL, Cappola AR, et al. Nonlinear multisystem physiological dysregulation associated with frailty in older women: implications for etiology and treatment. J Gerontol A Biol Sci Med Sci 2009;64:1049-1057.
26. Ferrucci L, Guralnik JM. Mobility in human aging: a multidisciplinary life span conceptual framework. Ann Rev Gerontol Geriatr 2013;33:171-192.
27. Alves G, Larsen JP, Emre M, Wentzel-Larsen T, Aarsland D. Changes in motor subtype and risk for incident dementia in Parkinson's disease. Mov Disord 2006; 21:1123-1130.
28. Taylor JP, Rowan EN, Lett D, O'Brien JT, McKeith IG, Burn DJ. Poor attentional function predicts cognitive decline in patients with non-demented Parkinson's disease independent of motor phenotype. J Neurol Neurosurg Psychiatry 2008;79:1318-1323.
29. Gibb W. Dementia and Parkinson's disease. Br J Psychiatry 1989;154:596-614.
30. Mahler ME, Cummings JL. Alzheimer disease and the dementia of Parkinson disease: comparative investigations. Alzheimer Dis Assoc Discord 1990;4:133-149.
31. Churchyard A, Lees A. The relationship between dementia and direct involvement of the hippocampus and amygdala in Parkinson's disease. Neurology 1997;49:1570-1576.
32. Jellinger KA. Morphological substrates of mental dysfunction in Lewy body disease: an update. J Neural Transm Suppl 2000;59(suppl):185-212.
33. Jellinger KA. Alpha-synuclein pathology in Parkinson's and Alzheimer's disease brain: incidence and topographic distribution-a pilot study. Acta Neuropathol 2003;106: 191-201.
34. Hughes TA, Ross HF, Musa S, et al. A 10-year study of the incidence of and factors predicting dementia in Parkinson's disease. Neurology 2000;54:1596-1602.
35. Kalaitzakis ME, Pearce RK. The morbid anatomy of dementia in Parkinson's disease. Acta Neuropathol 2009; 118:587-598.
36. Muller ML, Frey KA, Petrou M, et al. b-Amyloid and postural instability and gait difficulty in Parkinson's disease at risk for dementia. Mov Disord 2013;28:296-301.